Research Access Program

Precipio will make available a limited number of ICE COLD-PCR mutation enrichment reagents (ICEme reagents) to cancer researchers who intend to conduct research in liquid biopsies and publish their work in peer-reviewed journals. Precipio will also offer access to their High Resolution Analysis (HRM) technology coupled with ICE COLD-PCR (ICP) for liquid biopsy. Precipio is interested in generating compelling studies and publications that will include ICP technology as a centerpiece of the study.

• Complimentary ICEme reagents for liquid biopsy research
• Access to HRM coupled with ICE COLD-PCR (ICP)
• Technical training for staff (on-site or web-based) on ICP with Sanger or Real-time PCR
• Early access to future ICEme reagents before commercially available
• Support researchers efforts to publish their findings
• Ability to offer ICP enabled liquid biopsy technology to physicians for clinical applications once validated

Precipio will offer preferential pricing to any Research Access Program partner that would like to offer the ICP liquid biopsy technology for clinical applications to their physicians and patients.